breast cancer誌の現状と impact...
TRANSCRIPT
Breast Cancer誌の現状と Impact Factorについて
The Japanese Breast Cancer Society 14 July 2017
www.springer.com/12282
1
Contents
• New Submission / Acceptance Rate
1. Editorial Development
• Production Volume / Published Articles
2. Production
• Top 10 Article Downloads
3. Usage
• Impact Factor / Highly Cited Articles
4. Impact
2
1.0
1 Editorial Development
3
1 Editorial Development
1.1 Editorial Status Summary
Submissions 2012 2013 2014 2015 2016 2017
Total Submitted 297 256 280 329 368 202
Total Decisioned * 289 261 272 315 349 210
Accept 103 75 67 82 76 37
Reject 182 186 198 222 271 173
Acceptance Rate 35.6% 28.7% 24.6% 26.0% 21.8% 17.6%
Average Days to Accept ** 104.8 113.1 98.6 94.5 106.5 101.8
Average Days to Reject 35.0 37.8 34.3 29.1 30.4 29.4
Average Days to First Decision 29.1 30.8 30.9 25.9 28.2 26.9
Disclaimer: * Only the papers for which the ‘Final Decision’ has been set are taken into account. ** Including days with author.
(Source: Editorial Manager, as of 30 Jun 2017)
4
1 Editorial Development 1.2 New Submissions by Article Type
(Source: Editorial Manager, as of 30 Jun 2017)
Article type 2012 2013 2014 2015 2016 2017
Special Feature 9 4 10 11 7 3
Special Article 0 0 0 4 0 0
Conference Paper 2 0 0 0 0 0
Review Article 13 13 18 25 30 26
Original Article 183 179 194 235 279 146
Case Report 82 52 49 47 43 19
Rapid Communication 2 1 5 5 5 3
Editorial 2 2 1 1 2 0
Letters to the Editor 4 5 3 1 2 5
Total 297 256 280 329 368 202
13 13 18
25 30 26
183 179
194
235
279
146
82
52
49
47
43
19
0
50
100
150
200
250
300
350
400
2012 2013 2014 2015 2016 2017
Letters to the Editor
Editorial
Rapid Communication
Case Report
Original Article
Review Article
Conference Paper
Special Article
Special Feature
5
1 Editorial Development 1.3 Accepted Articles by Article Type
(Source: Editorial Manager, as of 30 Jun 2017)
Article type 2012 2013 2014 2015 2016 2017
Special Feature 7 7 8 12 7 4
Special Article 0 0 0 4 0 0
Conference Paper 1 1 0 0 0 0
Review Article 8 4 4 6 8 3
Original Article 74 56 51 56 57 24
Case Report 9 3 0 2 2 1
Rapid Communication 1 1 2 0 1 0
Editorial 1 0 1 1 1 0
Letters to the Editor 2 3 1 1 0 5
Total 103 75 67 82 76 37 7 7 8 12
7 4
8 4 4
6
8 3
74
56 51
56
57
24
0
20
40
60
80
100
120
2012 2013 2014 2015 2016 2017
Letters to the Editor
Editorial
Rapid Communication
Case Report
Original Article
Review Article
Conference Paper
Special Article
Special Feature
6
1 Editorial Development 1.4 Acceptance Rate by Article Type
(Source: Editorial Manager, as of 30 Jun 2017)
Article type 2012 2013 2014 2015 2016 2017
Special Feature 100 100 100 100 100 100
Special Article — — — 100 — —
Conference Paper 100 100 — — — —
Review Article 57.1 36.4 25.0 25.0 26.7 12.5
Original Article 42.3 31.1 26.3 25.6 21.8 15.5
Case Report 10.7 5.6 0 4.2 4.7 5.6
Rapid Communication 50.0 100 50.0 0 20.0 0
Editorial 50.0 0 100 100 50.0 —
Letters to the Editor 50.0 60.0 100 50.0 0 83.3
Total 35.6 28.7 24.6 26.0 21.8 17.6
Total (excl. SF, SA, CP, Ed) 32.5 25.7 21.3 20.6 19.5 16.0
0
10
20
30
40
50
60
2012 2013 2014 2015 2016 2017
Review Article Original Article
Case Report Total
(%)
(%)
7
1 Editorial Development 1.5 New Submissions by Location
(Source: Editorial Manager, as of 30 Jun 2017)
133
86 89 109
80 37
58 80
84 94
124 69
16 17 20 19
34
7
40 22 43 43
45
26
43 42
38 52
68 54
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2012 2013 2014 2015 2016 2017
Africa
Pacific
Middle East
Europe
Americas
Asia
Japan
Country / Region 2012 2013 2014 2015 2016 2017
Japan 133 86 89 109 80 37
Asia 58 80 84 94 124 69
Americas 16 17 20 19 34 7
Europe 40 22 43 43 45 26
Middle East 43 42 38 52 68 54
Pacific 1 1 0 1 2 1
Africa 6 8 6 11 15 8
Total 297 256 280 329 368 202
8
1 Editorial Development 1.6 Acceptance Rate by Location
(Source: Editorial Manager, as of 30 Jun 2017)
Country / Region 2012 2013 2014 2015 2016 2017
Japan 52.1 51.0 51.9 53.8 50.0 47.7
Asia 27.7 14.1 12.9 14.9 13.5 8.7
Americas 11.8 13.3 18.2 11.8 8.8 11.1
Europe 26.3 23.8 17.9 19.0 26.7 7.4
Middle East 13.2 17.5 7.3 1.9 7.9 11.8
Pacific 0 — 100 0 0 50.0
Africa 0 0 0 18.2 7.1 0
Total 35.6 28.7 24.6 26.0 21.8 17.6
0
10
20
30
40
50
60
2012 2013 2014 2015 2016 2017
Japan AsiaAmericas EuropeMiddle East Total
(%)
(%)
9
2.0
2 Production
10
Year Vol / Issue publication date
articles per issue
pages per issue
2016
23 / 1 23 Dec 2015 22 166
23 / 2 19 Feb 23 162
23 / 3 20 Apr 22 204
23 / 4 16 Jun 21 152
23 / 5 25 Aug 17 128
23 / 6 26 Oct 19 140
Total 124 952
2017
24 / 1 4 Jan 22 170
24 / 2 20 Feb 18 174
24 / 3 23 Apr 22 148
24 / 4 Jul 21 150
Subtotal 83 642
2 Production 2.1 Production Volume 2.2 Published Articles
18 14 18 20 11 11 5
12 16 11
2
3 2 3
5 5 5
5 4
8
7
16 26 22 30 29
76 58
92
57 6 13 9 8
9 8
18
12
5
1
324 315 310 328 371 372
787
670
951
642
0
100
200
300
400
500
600
700
800
900
1000
0
20
40
60
80
100
120
140
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Special Feature Special Article Conference Paper
Review Article Original Article Case Report
Rapid Communication Editorial Letter To The Editor
Author’s Reply Erratum Retraction
Others No. of pages
11
3.0
3 Usage
12
Title Author Article Type Year Vol Issue Page Downloads
Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer
Kosuke Kawaguchi
Original Article 2017 24 1 111 814
Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells
Angelika Kaczyńska
Original Article 2017 24 2 271 757
HER2-directed therapy: current treatment options for HER2-positive breast cancer Shahid Ahmed Review
Article 2015 22 2 101 735
Assessment of pain, acceptance of illness, adjustment to life with cancer and coping strategies in breast cancer patients
Aleksandra Czerw
Original Article 2016 23 4 654 735
A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
Eiichi Shiba Original Article 2016 23 3 499 703
Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold? Shigehira Saji Special
Feature 2016 23 1 1 679
Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer
Shinzaburo Noguchi
Original Article 2016 23 5 771 645
The pharmacological and hormonal therapy of hot flushes in breast cancer survivors
Iwona Wiśniewska
Review Article 2016 23 2 178 568
Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections
Rieko Nishimura
Original Article 2016 23 6 917 567
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
Shinzaburo Noguchi
Original Article 2014 21 6 703 560
(Source: COUNTER Reporting / Business Warehouse)
3 Usage 3.1 Top 10 Full-Text Article Downloads 2016
13
4.0
4 Impact
14 4 Impact
4.1 Impact Factorとは？
自然科学176 分野8,600 誌以上、社会科学56 分野3,100 誌以上の
Science Citation Index® Expanded 及び Social Sciences Citation Index 収録の
雑誌を対象にした評価指標の一つ。
特定の1年間において、ある雑誌に掲載された「平均的な論文」が
どの程度頻繁に引用されているかを示す尺度。
注）「平均的な論文」とは、原著論文、総説等、研究結果をまとめた論文を指す。
Editorial や Letter は除外される。
一般に、その雑誌の関連分野における影響度を表す。
(Source: http://ip-science.thomsonreuters.jp/media/support/jcr/ImpactFactor_QRC.pdf)
15 4 Impact
4.2 Impact Factor の計算方法
(Source: http://ip-science.thomsonreuters.jp/media/support/jcr/ImpactFactor_QRC.pdf)
注1： 2014年issue収載論文に2012-2013年時点でオンライン出版されている論文が引用されていれば、
分子に数えられる。
注2： 2014年出版のオンライン論文（issue 未収載）に2012-2013年issue 収載論文が引用されても、
そのオンライン論文が2014年発行のissue に収載されない限り、分子には数えられない。
16 4 Impact
4.3 Impact Factor of Breast Cancer
(Source: Clarivate Analytics, Journal Citation Reports, as of 14 Jun 2017)
2010 2011 2012 2013 2014 2015 2016
Impact Factor 1.888 1.363 1.330 1.505 1.585 1.170 1.572
Number of cites to articles published in two years before 124 75 80 75 111 58 174
Number of cites to articles published in a previous year 61 64 53 80 57 128 120
Number of articles published in two years before 47 51 51 49 54 52 107
Number of articles published a previous year 51 51 49 54 52 107 80
Rank among oncology journals 125/184 149/194 160/196 162/202 169/211 191/213 183/217
5-Year Impact Factor ― ― ― 1.401 1.490 1.412 1.561
Self Cites 6% 3% 6% 1% 3% 1% 5%
185 139 133 155 168 186
294
98 102 100 103 106 159 187
1.888 1.363 1.330
1.505 1.585
1.170
1.572
0.000
0.500
1.000
1.500
2.000
0
50
100
150
200
250
300
350
2010 2011 2012 2013 2014 2015 2016
Number of cites to articlespublished in last two years (a)
Number of articles published inlast two years (b)
Impact Factor (a/b)
17 4 Impact
4.4 Cited Journal Data
(Source: Clarivate Analytics, Journal Citation Reports, as of 14 Jun 2017)
Impact Factor Citing Journal
Cited year Impact Factor Citing Journal
Cited year All years 2014-2015 All years 2014-2015
1.572 BREAST CANCER 77 16 2.297 BREAST J 10 2 5.168 ONCOTARGET 29 9 2.801 BREAST 9 4 3.522 EJSO-EUR J SURG ONC 24 4 1.745 SURG TODAY 9 2 3.626 BREAST CANCER RES TR 23 7 2.494 ULTRASOUND MED BIOL 8 2 3.288 BMC CANCER 23 11 24.008 J CLIN ONCOL 7 1 1.653 ONCOTARGETS THER 23 6 3.523 HISTOPATHOLOGY 7 1 2.806 PLOS ONE 22 5 3.226 INT J MOL SCI 7 1 4.041 ANN SURG ONCOL 20 3 2.816 CLIN BREAST CANCER 7 1 1.390 ONCOL LETT 20 6 2.698 SUPPORT CARE CANCER 7 1 4.259 SCI REP-UK 15 3 1.600 WORLD J SURG ONCOL 7 1 3.967 EUR RADIOL 12 1 6.345 BREAST CANCER RES 6 2 3.650 TUMOR BIOL 11 4 2.735 STRAHLENTHER ONKOL 6 0 1.937 ANTICANCER RES 11 1 2.400 AM J CLIN PATHOL 6 3 1.803 MEDICINE 11 5 2.204 J BREAST CANCER 6 1 1.706 INT J CLIN EXP PATHO 11 2 1.130 SPRINGERPLUS 6 0 3.362 CANCER MED-US 10 3 1.069 INT J CLIN EXP MED 6 2 2.687 J CLIN PATHOL 10 3 ALL Journals 1,203 294
18 4 Impact 4.5 Highly Cited Articles Published in Breast Cancer (2014-2015), Cited in 2016
(Source: Clarivate Analytics, Web of Science, as of 14 Jun 2017)
Title Author Article type Year Vol Issue Page Citations
Functional significance of long non-coding RNAs in breast cancer Rajeev Vikram Review Article 2014 21 5 515 12
HER2-directed therapy: current treatment options for HER2-positive breast cancer Shahid Ahmed Review Article 2015 22 2 101 12
Prognostic significance of NANOG and KLF4 for breast cancer Takuya Nagata Original Article 2014 21 1 96 10
Meta-analysis of the effects of exercise intervention on quality of life in breast cancer survivors Yingchun Zeng Review
Article 2014 21 3 262 9
Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer Tatsuya Yoshioka Original
Article 2015 22 2 185 8
Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response Patricio Godoy Original
Article 2014 21 4 491 7
Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer Rie Horii Original
Article 2014 21 5 598 7
Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011
Junichi Kurebayashi
Special Article 2015 22 3 235 7
Efficacy of manual lymphatic drainage and intermittent pneumatic compression pump use in the treatment of lymphedema after mastectomy: a randomized controlled trial
Hulya Uzkeser Original Article 2015 22 3 300 7
19 4 Impact 4.5 ― continued ―
(Source: Clarivate Analytics, Web of Science, as of 14 Jun 2017)
Title Author Article type Year Vol Issue Page Citations
Photoacoustic mammography: initial clinical results Toshiyuki Kitai Original Article 2014 21 2 146 6
Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer Eriko Tokunaga Original
Article 2014 21 3 341 6
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
Shinzaburo Noguchi
Original Article 2014 21 6 703 6
Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells Akira I. Hida Original
Article 2015 22 2 129 6
Thioglucose-bound gold nanoparticles increase the radiosensitivity of a triple-negative breast cancer cell line (MDA-MB-231) Cuihong Wang Original
Article 2015 22 4 413 6
Reversine induces cell cycle arrest, polyploidy, and apoptosis in human breast cancer cells Chin-Ho Kuo Original
Article 2014 21 3 358 5
A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer
Fatemeh Bahreini
Original Article 2015 22 6 615 5
20 4 Impact 4.6 Highly Cited Articles Published in Breast Cancer (2011-2015), Cited in 2016
(Source: Clarivate Analytics, Web of Science, as of 14 Jun 2017)
Title Author Article type Year Vol Issue Page Citations
Role of stromal myofibroblasts in invasive breast cancer: stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome
Masako Yamashita
Original Article 2012 19 2 170 16
The roles of TGF-beta signaling in carcinogenesis and breast cancer metastasis Takeshi Imamura
Special Feature 2012 19 2 118 12
Functional significance of long non-coding RNAs in breast cancer Rajeev Vikram
Review Article 2014 21 5 515 12
HER2-directed therapy: current treatment options for HER2-positive breast cancer Shahid Ahmed
Review Article 2015 22 2 101 12
Prognostic significance of NANOG and KLF4 for breast cancer Takuya Nagata
Original Article 2014 21 1 96 10
Meta-analysis of the effects of exercise intervention on quality of life in breast cancer survivors
Yingchun Zeng
Review Article 2014 21 3 262 9
Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer
Tatsuya Yoshioka
Original Article 2015 22 2 185 8
Reproductive history and breast cancer risk Shunzo Kobayashi
Review Article 2012 19 4 302 7
Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response
Patricio Godoy
Original Article 2014 21 4 491 7
Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer Rie Horii Original
Article 2014 21 5 598 7
21 4 Impact 4.6 ― continued ―
(Source: Clarivate Analytics, Web of Science, as of 14 Jun 2017)
Title Author Article type Year Vol Issue Page Citations
Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011
Junichi Kurebayashi
Special Article 2015 22 3 235 7
Efficacy of manual lymphatic drainage and intermittent pneumatic compression pump use in the treatment of lymphedema after mastectomy: a randomized controlled trial
Hulya Uzkeser Original Article 2015 22 3 300 7
Improvement of survival and prospect of cure in patients with metastatic breast cancer
Yee Chung Cheng
Special Feature 2012 19 3 191 6
Is MRI useful for the prediction of nipple involvement? Naomi Sakamoto
Original Article 2013 20 4 316 6
Photoacoustic mammography: initial clinical results Toshiyuki Kitai Original Article 2014 21 2 146 6
Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer
Eriko Tokunaga
Original Article 2014 21 3 341 6
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
Shinzaburo Noguchi
Original Article 2014 21 6 703 6
Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells Akira I. Hida Original
Article 2015 22 2 129 6
Thioglucose-bound gold nanoparticles increase the radiosensitivity of a triple-negative breast cancer cell line (MDA-MB-231) Cuihong Wang Original
Article 2015 22 4 413 6
22 4 Impact
4.7 The Status of Competing Journals
Rank Journal title Impact Factor 2016
Impact Factor without journal self cites
5-Year Impact Factor
Citable items Total Cites IF2015 IF2014
3 Lancet Oncology 33.900 33.250 31.194 169 38,110 26.509 24.690
5 Journal of Clinical Oncology 24.008 23.087 19.311 478 149,617 20.982 18.443
27 Breast Cancer Research 6.345 6.131 6.468 123 10,541 5.211 5.490
68 Cancer Science 3.974 3.894 3.757 228 11,075 3.896 3.523
82 Breast Cancer Research and Treatment 3.626 3.415 4.069 332 18,721 4.085 3.940
118 Clinical Breast Cancer 2.816 2.728 2.768 88 1,788 3.082 2.107
119 Breast 2.801 2.661 2.833 153 3,749 2.740 2.381
144 Breast Journal 2.297 2.252 1.982 80 2,354 1.920 1.411
150 Journal of Breast Cancer 2.204 2.080 2.156 59 741 1.854 1.788
155 International Journal of Clinical Oncology 2.064 1.987 1.870 154 2,204 1.806 2.128
163 Japanese Journal of Clinical Oncology 1.905 1.784 1.931 167 4,321 1.889 2.016
183 Breast Cancer 1.572 1.487 1.561 113 1,203 1.182 1.585
184 Breast Care 1.553 1.495 1.383 55 543 1.645 0.627
(Source: Clarivate Analytics, Journal Citation Reports, as of 14 Jun 2017)